Zymaxid

Zymaxid is a brand name of gatifloxacin ophthalmic, approved by the FDA in the following formulation(s):

ZYMAXID (gatifloxacin - solution/drops; ophthalmic)

• 
  Manufacturer: ALLERGAN
  
  Approval date: May 18, 2010
  
  Strength(s): 0.5% ^[RLD]

Has a generic version of Zymaxid been approved?

No. There is currently no therapeutically equivalent version of Zymaxid available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zymaxid. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  8-alkoxyquinolonecarboxylic acid hydrate with excellent stability and process for producing the same
  Patent 5,880,283
  Issued: March 9, 1999
  Inventor(s): Matsumoto; Toyomi & Hara; Masamoto & Miyashita; Kunio & Kato; Yukihiro
  Assignee(s): Kyorin Pharmaceutical Co., Ltd.
  The invention provides 1-cyclopropyl-6-fluoro-1,4- dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3- quinolinecarboxylic acid sesquihydrate with excellent stability represented by a following formula (1), ##STR1## and process for producing the same.
  
  Patent expiration dates:
  
  
  • December 5, 2015
    
    ✓ 
    Drug substance
  
  
  
  • June 5, 2016
    
    ✓ 
    Pediatric exclusivity
  
  



• 
  Aqueous liquid pharmaceutical composition comprised of gatifloxacin
  Patent 6,333,045
  Issued: December 25, 2001
  Inventor(s): Yasueda; Shinichi & Inada; Katsuhiro
  Assignee(s): Senju Pharmaceutical Co., Ltd.
  Kyorin Pharmaceutical Co., Ltd.
  There is provided an aqueous liquid pharmaceutical composition which comprises Gatifloxacin (chemical nomenclature: (.+-.)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazi nyl)-4-oxo-3-quinoline carboxylic acid) or its salt and disodium edetate. Further, there are provided a method for raising corneal permeability of Gatifloxacin, a method for preventing precipitation of Gatifloxacin crystals, and a method for preventing coloration of Gatifloxacin by incorporating disodium edetate into an aqueous liquid preparation containing Gatifloxacin or its salt.
  
  Patent expiration dates:
  
  
  • August 20, 2019
    
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  
  
  • February 20, 2020
    
    ✓ 
    Pediatric exclusivity
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • May 18, 2013 - NEW PRODUCT
  
  

See also...

• Zymaxid Consumer Information (Drugs.com)
• Zymaxid Advanced Consumer Information (Micromedex)
• Gatifloxacin Drops Consumer Information (Wolters Kluwer)
• Gatifloxacin ophthalmic Consumer Information (Cerner Multum)
• Gatifloxacin Ophthalmic Advanced Consumer Information (Micromedex)
• Gatifloxacin eent AHFS DI Monographs (ASHP)